Literature DB >> 29587299

Chronic Obstructive Pulmonary Disease in Lung Cancer Patients: Prevalence, Underdiagnosis, and Clinical Characterization.

Cecilia Mouronte-Roibás1,2, Virginia Leiro-Fernández1,2, Alberto Ruano-Raviña3, Cristina Ramos-Hernández1,2, José Abal-Arca4, Isaura Parente-Lamelas4, Maribel Botana-Rial1,2, Ana Priegue-Carrera1,2, Alberto Fernández-Villar1,2.   

Abstract

BACKGROUND: Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) are associated with increased morbidity and mortality. The differential clinical and functional features among LC patients with or without COPD have not been defined.
OBJECTIVES: The aims of this study were to examine the prevalence and underdiagnosis rate of COPD in LC patients and to compare the clinical and functional features of LC patients with and without COPD.
METHODS: We designed a multicenter hospital-based study including all LC cases diagnosed from January 2014 to August 2016. We assessed epidemiological, clinical, radiological, functional, and histological variables in all cases.
RESULTS: We recruited 602 patients with LC, most of them men (77.9%), with a median age of 67 ± 15 years. The COPD prevalence among LC patients was 51.5%, with a underdiagnosis rate of 71.6%. The LC+COPD patients were older and the proportion of men was higher compared with the LC-only patients. The LC+COPD patients had more pack-years, more squamous LC, a lower monoxide transfer coefficient (KCO), and higher Charlson index scores than patients with LC only. The median survival of LC-only patients was 37% longer than that of LC+COPD patients (22 vs. 16 months), but this difference was not statistically significant.
CONCLUSIONS: Among LC patients, COPD is prevalent and underdiagnosed. Patients with LC+COPD more often have squamous LC, have greater comorbidities, and have a lower KCO. More effort should be made for an early diagnosis of COPD to select patients at higher risk of developing LC.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Lung cancer; Prevalence; Underdiagnosis

Mesh:

Year:  2018        PMID: 29587299     DOI: 10.1159/000487243

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  7 in total

1.  Lung cancer and chronic obstructive pulmonary disease: understanding the complexity of carcinogenesis.

Authors:  Cecilia Mouronte-Roibás; Alberto Ruano-Raviña; Alberto Fernández-Villar
Journal:  Transl Lung Cancer Res       Date:  2018-09

2.  Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer.

Authors:  Vinicius Cavalheri; Chris Burtin; Vittoria R Formico; Mika L Nonoyama; Sue Jenkins; Martijn A Spruit; Kylie Hill
Journal:  Cochrane Database Syst Rev       Date:  2019-06-17

3.  Early Loss of Fat Mass During Chemoradiotherapy Predicts Overall Survival in Locally Advanced Squamous Cell Carcinoma of the Lung, but Not in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

Authors:  A C H Willemsen; J H R J Degens; L W J Baijens; A-M C Dingemans; A Hoeben; F J P Hoebers; D K M De Ruysscher; A M W J Schols
Journal:  Front Nutr       Date:  2020-11-26

4.  A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer.

Authors:  Sophie Corriveau; Gregory R Pond; Grace H Tang; John R Goffin
Journal:  BMC Cancer       Date:  2021-01-05       Impact factor: 4.430

5.  Exercise training modalities in patients with lung cancer: a protocol for systematic review and network meta-analysis.

Authors:  Jiaju Lu; Runhong Lin; Chuchu Zhang; Meng Zhang; Yalei Wang; Yu Zhang
Journal:  BMJ Open       Date:  2022-09-29       Impact factor: 3.006

Review 6.  Non-small cell lung cancer in China.

Authors:  Peixin Chen; Yunhuan Liu; Yaokai Wen; Caicun Zhou
Journal:  Cancer Commun (Lond)       Date:  2022-09-08

7.  PCAF-mediated acetylation of ISX recruits BRD4 to promote epithelial-mesenchymal transition.

Authors:  Li-Ting Wang; Kwei-Yan Liu; Wen-Yih Jeng; Cheng-Ming Chiang; Chee-Yin Chai; Shyh-Shin Chiou; Ming-Shyang Huang; Kazunari K Yokoyama; Shen-Nien Wang; Shau-Ku Huang; Shih-Hsien Hsu
Journal:  EMBO Rep       Date:  2020-01-07       Impact factor: 8.807

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.